ZA9203210B - Pyrrolindinones - Google Patents

Pyrrolindinones

Info

Publication number
ZA9203210B
ZA9203210B ZA923210A ZA9203210A ZA9203210B ZA 9203210 B ZA9203210 B ZA 9203210B ZA 923210 A ZA923210 A ZA 923210A ZA 9203210 A ZA9203210 A ZA 9203210A ZA 9203210 B ZA9203210 B ZA 9203210B
Authority
ZA
South Africa
Prior art keywords
pyrrolindinones
Prior art date
Application number
ZA923210A
Inventor
Paul Elliot Bender
Elliot Bender Paul
Siegfried Benjamin Christen Iv
Benjamin Christensen Siegfried
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US69462491A priority Critical
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA9203210B publication Critical patent/ZA9203210B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
ZA923210A 1991-05-02 1992-05-04 Pyrrolindinones ZA9203210B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US69462491A true 1991-05-02 1991-05-02

Publications (1)

Publication Number Publication Date
ZA9203210B true ZA9203210B (en) 1993-03-31

Family

ID=24789624

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA923210A ZA9203210B (en) 1991-05-02 1992-05-04 Pyrrolindinones

Country Status (11)

Country Link
EP (1) EP0584208A4 (en)
JP (1) JPH06507405A (en)
CN (1) CN1067244A (en)
AP (1) AP9200379A0 (en)
AU (1) AU1917092A (en)
CA (1) CA2102106A1 (en)
IE (1) IE921376A1 (en)
MX (1) MX9202090A (en)
PT (1) PT100441A (en)
WO (1) WO1992019594A1 (en)
ZA (1) ZA9203210B (en)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
EP0672031B1 (en) * 1992-12-02 2003-03-12 Pfizer Inc. Catechol diethers as selective pde iv inhibitors
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
TW263495B (en) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
DE69433997T2 (en) * 1993-06-18 2005-01-27 Smithkline Beecham Corp. Method for identifying a PDE IV inhibitor
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
PT711282E (en) 1993-07-28 2002-11-29 Aventis Pharma Ltd Inhibitor compounds of pde iv and fnt
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
AT187447T (en) * 1993-11-26 1999-12-15 Pfizer 3-phenyl-2-isoxazolines derivatives as entzündugshemmende medium
CZ283564B6 (en) * 1993-11-26 1998-05-13 Pfizer Inc. 3-aryl-2-isoxazoline-5-hydroxamic acids and pharmaceutical compositions based thereon
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
DE69433594T2 (en) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Tri-substituted phenyl derivatives, to processes for their preparation and their use as inhibitors of phosphodiesterase (type IV)
CA2143143A1 (en) * 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
AU1326795A (en) * 1994-03-09 1995-09-25 Pfizer Inc. Isoxazoline compounds as 5-lipoxygenase inhibitors
DE69503769D1 (en) * 1994-03-09 1998-09-03 Pfizer Isoxazolines connection to inhibition tnf-release
EP1380291A1 (en) * 1994-04-21 2004-01-14 Schering Aktiengesellschaft PDE IV inhibitors for treating multiple sclerosis
PT758233E (en) * 1994-04-21 2004-04-30 Schering Ag Pde iv inhibitors for the treatment of multiple sclerosis
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
AT247116T (en) * 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
EP0804192A1 (en) * 1995-02-10 1997-11-05 Schering Aktiengesellschaft Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
DE19540475A1 (en) * 1995-10-20 1997-04-24 Schering Ag chiral methylphenyloxazolidinones
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
AU716376B2 (en) * 1996-06-25 2000-02-24 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (en) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド Fused polycyclic 2-aminopyrimidine derivatives, their use as their production and protein tyrosine kinase inhibitor
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
KR19980074060A (en) * 1997-03-21 1998-11-05 김윤배 Novel substituted 3,4-dialkoxyphenyl derivatives
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6680336B2 (en) 1999-12-15 2004-01-20 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
KR100755103B1 (en) * 2000-01-06 2007-09-04 사노피-아벤티스 Novel Tetrahydropyridines, Preparation Method and Pharmaceutical Compositions Containing Same
FR2803593B1 (en) * 2000-01-06 2002-02-15 Sanofi Synthelabo News tetrahydropyridine, process for their preparation and pharmaceutical compositions containing them
US6555572B2 (en) 2000-03-16 2003-04-29 Inflazyme Pharmaceuticals Ltd. Benzylated PDE4 inhibitors
IT1317049B1 (en) * 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Compounds useful for the preparation of medicaments having phosphodiesterase attivita'inibitrice iv.
WO2002081446A1 (en) * 2001-04-06 2002-10-17 Daewoong Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
WO2002081447A1 (en) * 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof
FR2823748B1 (en) * 2001-04-20 2004-02-20 Sanofi Synthelabo Tetrahydropyridyl-alkyl benzodiazines, process for their preparation and pharmaceutical compositions containing them
MXPA03010810A (en) 2001-05-29 2004-03-22 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments.
MXPA04003516A (en) * 2001-10-16 2004-07-23 Memory Pharm Corp 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes.
AU2003252259A1 (en) * 2002-07-26 2004-02-16 Nihon Nohyaku Co., Ltd. Novel haloalkylsulfonanilide derivatives, herbicides and usage thereof
JP2004107323A (en) * 2002-07-26 2004-04-08 Nippon Nohyaku Co Ltd New haloalkylsulfone anilide derivative, herbicide and use thereof
CA2507465C (en) 2002-11-26 2009-04-28 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
KR20060039392A (en) * 2003-04-16 2006-05-08 메모리 파마슈티칼스 코포레이션 Phosphodiesterase 4 inhibitors
BRPI0409888A (en) 2003-04-18 2006-05-23 Memory Pharm Corp pyrazole derivatives as phosphodiesterase 4 inhibitors, compound, pharmaceutical composition, method for inhibiting pde4 enzyme, enhancing cognition and / or treating psychosis in a patient, method for treating a patient having a disease involving levels de camp decreased, method for treating a patient suffering from an allergic or inflammatory disease and method for treating a patient suffering from neurodegeneration resulting from an illness or injury
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
EP1813284A1 (en) * 2004-10-13 2007-08-01 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical composition
WO2006044528A1 (en) 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
CN101166737A (en) 2004-10-20 2008-04-23 记忆药物公司 Phosphodiesterase 4 inhibitors
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag organic compounds.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AT549337T (en) 2006-04-21 2012-03-15 Novartis Ag Purine derivatives for use as adenosine a2a receptor agonists
MX2009003185A (en) 2006-09-29 2009-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors.
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
PL2104535T3 (en) 2007-01-10 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP5244904B2 (en) 2007-05-07 2013-07-24 ノバルティス アーゲー Organic compounds
KR101578235B1 (en) 2007-12-10 2015-12-16 노파르티스 아게 Oarganic compounds
CN101910153B (en) 2008-01-11 2014-01-22 诺华股份有限公司 Pyrimidines as kinase inhibitors
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
ES2396023T3 (en) 2009-01-29 2013-02-18 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
JP5775871B2 (en) 2009-08-20 2015-09-09 ノバルティス アーゲー Heterocyclic oxime compounds
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc Compounds and compositions as inhibitors of trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP2014505088A (en) 2011-02-10 2014-02-27 ノバルティス アーゲー [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
EA201391230A1 (en) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Compounds and compositions as trk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
ES2558457T3 (en) 2011-09-16 2016-02-04 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (en) 2013-03-15 2016-01-13 因特利凯有限责任公司 Combination of kinase inhibitors and uses thereof
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
BR112016024533A2 (en) 2014-04-24 2017-08-15 Novartis Ag amino pyrazine derivatives as phosphatidylinositol 3 kinase inhibitors
PT3134395T (en) 2014-04-24 2018-04-16 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6454727B2 (en) 2014-04-24 2019-01-16 ノバルティス アーゲー Aminopyridine derivatives as phosphatidylinositol 3-kinase inhibitors
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone
JPS4916872A (en) * 1972-04-21 1974-02-14
JPS5238227B2 (en) * 1972-06-14 1977-09-28
JPS5232064B2 (en) * 1972-06-14 1977-08-19
JPS5751384B2 (en) * 1974-04-25 1982-11-01
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
DE3823299A1 (en) * 1988-07-07 1990-01-11 Schering Ag Substituted phenyl-pyrrolidin-2-one, oxazolidin-2-one and imidazolidin-2-ones, their preparation and use in medicaments

Also Published As

Publication number Publication date
CN1067244A (en) 1992-12-23
WO1992019594A1 (en) 1992-11-12
AP9200379A0 (en) 1992-04-30
EP0584208A1 (en) 1994-03-02
EP0584208A4 (en) 1994-03-23
MX9202090A (en) 1992-11-01
PT100441A (en) 1993-09-30
CA2102106A1 (en) 1992-11-03
AU1917092A (en) 1992-12-21
JPH06507405A (en) 1994-08-25
IE921376A1 (en) 1992-11-04

Similar Documents

Publication Publication Date Title
US5143923B1 (en) Benzoisothiazole-and benzisoxazole-3-carboxamides
KR100246065B1 (en) Substituted 3-aminoquinuclidines
DE69216251D1 (en) Substituierte aryl- und heteroaryl-phenyloxazolidinone
KR100218594B1 (en) Bis-benzofuran-2-ones
DE69224906D1 (en) Thermotropes flüssig-kristallines segment-blockcopolymer
DE69222933D1 (en) Cholangiographiekatheter
DE69228822D1 (en) Intubationsvorrichtung
DE69129193D1 (en) Triterpenderivat
DE69228192D1 (en) Wellpappe-palette
DE69213441D1 (en) Analsphinkterprothese
GB2257579B (en) Pin-header
GB9102635D0 (en) Compounds
IL103319D0 (en) Novel 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
ZA9202154B (en) Transfers
SG48301A1 (en) New combination
HU9302889D0 (en) Contrast-materials containing melani9n-derivatives
DE69222628D1 (en) Wärmeisolationsmaterial
HU9303393D0 (en) Substituted 3-amino-quinuclidines
HU9203552D0 (en) Substituted biphenyl-pyridones
NZ243454A (en) (indolylmethylene)-2-oxindoles
HK1011348A1 (en) Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
DE69228486D1 (en) Thrombosefilter
IE921121A1 (en) GRF-Analogs II
HU9201031D0 (en) Rapamycine-xilyle-ethers
HUT63774A (en) Dust-inhaler